EqualOcean has learned that Rovono Surgical(Chinese: 瑞龙诺赋), a laparoscopic surgical robot developer, has completed a pre-B+ round of financing of nearly CNY 200 million.
In the medical scene, doctors, enterprises and other parties hope to promote advanced diagnosis and treatment technology to more hospitals. In current clinical applications, all-in-one surgical robots are more common. Still, the price of imported laparoscopic surgical robots is in the tens of millions of yuan. The price of robot-assisted laparoscopic surgery is higher than that of ordinary laparoscopic surgery by 40,000-50,000 yuan, and most of them are paid by patients themselves. In addition, surgeons need at least one learning cycle of more than 30 surgeries to master the technology.
Currently, Chinese hospitals purchase a da Vinci surgical robot at a cost of about 20-30 million yuan, plus the cost of specialized consumables and an average of 1.5 million yuan per year in maintenance costs. A brokerage firm once estimated that the average additional cost per da Vinci surgery is about CNY44,000, of which CNY18,000 is the start-up fee paid by the patient. The high cost also affects the penetration of surgical robots in different departments in China: urology, represented by prostate cancer treatment, has the highest RAS penetration rate of 44%; thoracic surgery, represented by lung cancer treatment, has an RAS penetration rate of only 5%; and gynecology and general surgery, which account for 99% of the volume of minimally invasive soft tissue surgery, have an RAS penetration rate of less than 1%.
To solve the problem, Rovano Surgical has developed its own split modular surgical robot to cover more specialties. It is reported that it is the company's entire self-research, independent innovation of the split modular surgical robot, the design and development of which takes full account of the actual clinical surgical needs of minimally invasive surgeons, with a modular, dexterous, configurable solution, which not only reduces the economic burden of robotic-assisted surgery (RAS), but also improves the surgeon's surgical experience, expands the robotic surgical multi-specialty procedures, and promotes the comprehensive popularization of RAS. RAS will be widely popularized.
In order to reduce costs and achieve specialty coverage, Rovono Surgical's founder Changzheng Ma and co-founder Ying Mao led the team to develop a modular, dexterous surgical robot that can be set up in different combinations depending on the clinical needs of the hospital, consisting of a main console, different numbers of surgical arm carts, 3D laparoscopes, and executive surgical instruments. components.
The company's core differentiation is considered to be the development of modular, dexterous laparoscopic surgical robots, which can be better adapted to the needs of different departments in different hospitals, and also further improve the standardization of surgical processes, shorten the training period, and also be in line with the basis of the healthcare system in China and the current ability to pay.
This round of financing was led by NRL Capital (Chinese: 纽尔利资本), followed by Yipu Capital (Chinese: 翼朴资本), in addition to all of the company's existing shareholders. Proceeds from the financing will be used for the Company's product registration and R&D, accelerating the landing of the modular surgical robot, and brand promotion.